Cargando…

Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India

BACKGROUND: Coronavirus disease 2019 (COVID-19) vaccination campaigns are trying to curb the pandemic by vaccinating as many individuals and as quickly as possible. The speed of immunization depends upon the availability of the vaccine and vaccine uptake by the communities, which in turn is related...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansal, Yashik, Chand, Pragya, Bansal, Naveen, Singh, Pushpendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254787/
https://www.ncbi.nlm.nih.gov/pubmed/35800545
http://dx.doi.org/10.4103/jfmpc.jfmpc_2103_21
_version_ 1784740776916287488
author Bansal, Yashik
Chand, Pragya
Bansal, Naveen
Singh, Pushpendra
author_facet Bansal, Yashik
Chand, Pragya
Bansal, Naveen
Singh, Pushpendra
author_sort Bansal, Yashik
collection PubMed
description BACKGROUND: Coronavirus disease 2019 (COVID-19) vaccination campaigns are trying to curb the pandemic by vaccinating as many individuals and as quickly as possible. The speed of immunization depends upon the availability of the vaccine and vaccine uptake by the communities, which in turn is related to vaccine hesitancy, the safety/efficacy profile of the vaccines, and adverse events following immunization (AEFI) OBJECTIVES: (i) To study the AEFI experienced by vaccine recipients and (ii) to assess the subjective effect of these AEFI on the vaccine recipients, that is, perceived disability and opinion regarding taking the vaccine’s second dose METHODS: This was a cross-sectional study conducted at a tertiary care hospital where a questionnaire was distributed to the medical students who had taken at least one dose of a COVID-19 vaccine RESULTS: Out of 208 participants, more than three-quarters (n = 169, 81.2%) experienced AEFI symptoms within 12 hours of vaccination. The commonest symptoms were pain at the injection site (n = 173, 83.2%), body aches (n = 91, 43.8%), fever (n = 88, 42.3%), weakness (n = 86, 41.3%), and headache (n = 72, 34.6%). A majority of the participants reported complete recovery within 13–24 hours. Complete recovery was seen in all the study participants, and no serious event was seen. Twenty (10%) participants reported that they were not confident in taking the second dose of the vaccine CONCLUSIONS: The disability perceived by the vaccine recipients should be taken into consideration in a vaccine with a multi-dose schedule. Pitfalls in alleviating the immunization-related anxiety should be identified and addressed.
format Online
Article
Text
id pubmed-9254787
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-92547872022-07-06 Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India Bansal, Yashik Chand, Pragya Bansal, Naveen Singh, Pushpendra J Family Med Prim Care Original Article BACKGROUND: Coronavirus disease 2019 (COVID-19) vaccination campaigns are trying to curb the pandemic by vaccinating as many individuals and as quickly as possible. The speed of immunization depends upon the availability of the vaccine and vaccine uptake by the communities, which in turn is related to vaccine hesitancy, the safety/efficacy profile of the vaccines, and adverse events following immunization (AEFI) OBJECTIVES: (i) To study the AEFI experienced by vaccine recipients and (ii) to assess the subjective effect of these AEFI on the vaccine recipients, that is, perceived disability and opinion regarding taking the vaccine’s second dose METHODS: This was a cross-sectional study conducted at a tertiary care hospital where a questionnaire was distributed to the medical students who had taken at least one dose of a COVID-19 vaccine RESULTS: Out of 208 participants, more than three-quarters (n = 169, 81.2%) experienced AEFI symptoms within 12 hours of vaccination. The commonest symptoms were pain at the injection site (n = 173, 83.2%), body aches (n = 91, 43.8%), fever (n = 88, 42.3%), weakness (n = 86, 41.3%), and headache (n = 72, 34.6%). A majority of the participants reported complete recovery within 13–24 hours. Complete recovery was seen in all the study participants, and no serious event was seen. Twenty (10%) participants reported that they were not confident in taking the second dose of the vaccine CONCLUSIONS: The disability perceived by the vaccine recipients should be taken into consideration in a vaccine with a multi-dose schedule. Pitfalls in alleviating the immunization-related anxiety should be identified and addressed. Wolters Kluwer - Medknow 2022-05 2022-05-14 /pmc/articles/PMC9254787/ /pubmed/35800545 http://dx.doi.org/10.4103/jfmpc.jfmpc_2103_21 Text en Copyright: © 2022 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Bansal, Yashik
Chand, Pragya
Bansal, Naveen
Singh, Pushpendra
Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India
title Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India
title_full Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India
title_fullStr Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India
title_full_unstemmed Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India
title_short Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India
title_sort vaccine hesitancy after taking the first dose of covid-19 vaccine: a challenge for the covid-19 vaccination program in india
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254787/
https://www.ncbi.nlm.nih.gov/pubmed/35800545
http://dx.doi.org/10.4103/jfmpc.jfmpc_2103_21
work_keys_str_mv AT bansalyashik vaccinehesitancyaftertakingthefirstdoseofcovid19vaccineachallengeforthecovid19vaccinationprograminindia
AT chandpragya vaccinehesitancyaftertakingthefirstdoseofcovid19vaccineachallengeforthecovid19vaccinationprograminindia
AT bansalnaveen vaccinehesitancyaftertakingthefirstdoseofcovid19vaccineachallengeforthecovid19vaccinationprograminindia
AT singhpushpendra vaccinehesitancyaftertakingthefirstdoseofcovid19vaccineachallengeforthecovid19vaccinationprograminindia